AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1332-1338

  Lu, Lian ^a   Luo, Shun Tao ^a   Shi, Hua Shan ^a   Li, Meng ^a   Zhang, Hai Long ^a   He, Sha Sha ^a   Liu, Yan ^a   Pan, Ying ^a   Yang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

AAV2; Long term expression; Metastasis; Tumor; VEGF Trap

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN 1; FIBROBLAST GROWTH FACTOR; PARVOVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; DRUG POTENCY; DRUG SAFETY; FEMALE; GENE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MICROVESSEL DENSITY; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TOXICITY TESTING; TUMOR GROWTH; VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP GENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RIBONUCLEASE, PANCREATIC; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866450580     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1915     Document Type: Article

References (37)

1. Sharma RA, Harris AL, Dalgleish AG, Steward WP and O'Byrne KJ: Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2: 726-732, 2001.
2. Teo NB, Shoker BS, Martin L, Sloane JP and Holcombe C: Angiogenesis in pre-invasive cancers. Anticancer Res 22: 2061-2072, 2002.
3. Kieran MW and Billett A: Antiangiogenesis therapy. Current and future agents. Hematol Oncol Clin North Am 15: 835-851, viii, 2001.
4. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
5. Pour L, Hajek R, Buchler T, Maisnar V and Smolej L: Angiogenesis and antiangiogenic cancer therapy. Vnitr Lek 50: 930-938, 2004 (In Czech).
6. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
7. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
8. Moses MA and Langer R: A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 47: 230-235, 1991.
9. Rastinejad F, Polverini PJ and Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56: 345-355, 1989.
10. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
11. Jain RK: Molecular regulation of vessel maturation. Nat Med 9: 685-693, 2003.
12. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
13. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
14. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
15. Millauer B, Shawver LK, Plate KH, Risau W and Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994.
16. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398, 2002.
17. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99: 11399-11404, 2002.
18. Gomez-Manzano C, Holash J, Fueyo J, et al: VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10: 940-945, 2008.
19. Zaiss AK and Muruve DA: Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 15: 808-816, 2008.
20. Herzog RW, Yang EY, Couto LB, et al: Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5: 56-63, 1999.
21. Wang L, Takabe K, Bidlingmaier SM, Ill CR and Verma IM: Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 96: 3906-3910, 1999.
22. Ponnazhagan S, Mahendra G, Kumar S, et al: Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 64: 1781-1787, 2004.
23. Collins SA, Buhles A, Scallan MF, et al: AAV2-mediated in vivo immune gene therapy of solid tumours. Genet Vaccines Ther 8: 8, 2010.
24. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
25. Paley PJ, Staskus KA, Gebhard K, et al: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98-106, 1997.
26. Heist RS, Zhai R, Liu G, et al: VEGF polymorphisms and survival in early-stage non-small cell lung cancer. J Clin Oncol 26: 856-862, 2008.
27. Johnson DE, Lee PL, Lu J and Williams LT: Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 10: 4728-4736, 1990.
28. Basilico C and Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115-165, 1992.
29. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
30. Ferrara N and Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364, 1999.
31. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
32. Van Hinsbergh VW, Collen A and Koolwijk P: Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors. Ann Oncol 10 (Suppl 4): S60-S63, 1999.
33. Kuo CJ, Farnebo F, Yu EY, et al: Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98: 4605-4610, 2001.
34. Ferrara N, Chen H, Davis-Smyth T, et al: Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336-340, 1998.
35. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z and Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628, 1999.
36. Gerber HP, Kowalski J, Sherman D, Eberhard DA and Ferrara N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258, 2000.
37. Folkman J: Antiangiogenic gene therapy. Proc Natl Acad Sci USA 95: 9064-9066, 1998.